- Home
- ARQQ vs ABVX Comparison
ARQQ vs ABVX Comparison
Compare ARQQ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- ABVX
- Stock Information
- Founded
- ARQQ 2017
- ABVX 2013
- Country
- ARQQ United Kingdom
- ABVX France
- Employees
- ARQQ N/A
- ABVX N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- ABVX
- Sector
- ARQQ Technology
- ABVX
- Exchange
- ARQQ Nasdaq
- ABVX Nasdaq
- Market Cap
- ARQQ 531.6M
- ABVX 511.3M
- IPO Year
- ARQQ N/A
- ABVX N/A
- Fundamental
- Price
- ARQQ $35.01
- ABVX $72.07
- Analyst Decision
- ARQQ Strong Buy
- ABVX Buy
- Analyst Count
- ARQQ 1
- ABVX 7
- Target Price
- ARQQ $52.00
- ABVX $74.86
- AVG Volume (30 Days)
- ARQQ 842.4K
- ABVX 3.1M
- Earning Date
- ARQQ 05-22-2025
- ABVX 08-11-2025
- Dividend Yield
- ARQQ N/A
- ABVX N/A
- EPS Growth
- ARQQ N/A
- ABVX N/A
- EPS
- ARQQ 0.48
- ABVX N/A
- Revenue
- ARQQ $241,000.00
- ABVX $11,444,012.00
- Revenue This Year
- ARQQ $284.30
- ABVX N/A
- Revenue Next Year
- ARQQ $415.45
- ABVX $41.36
- P/E Ratio
- ARQQ $72.85
- ABVX N/A
- Revenue Growth
- ARQQ N/A
- ABVX 128.98
- 52 Week Low
- ARQQ $3.72
- ABVX $4.77
- 52 Week High
- ARQQ $52.79
- ABVX $75.51
- Technical
- Relative Strength Index (RSI)
- ARQQ 41.69
- ABVX 93.66
- Support Level
- ARQQ $32.77
- ABVX $69.37
- Resistance Level
- ARQQ $35.89
- ABVX $75.51
- Average True Range (ATR)
- ARQQ 3.63
- ABVX 3.15
- MACD
- ARQQ -1.34
- ABVX 4.05
- Stochastic Oscillator
- ARQQ 7.56
- ABVX 94.81
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.